<DOC>
	<DOCNO>NCT01479387</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Zevalin ( ibritumomab tiuxetan ) Japan . In-111 Zevalin , first , injected patient gamma scan imaging ass biodistribution Zevalin . When image show alter distribution , Y-90 Zevalin inject patient actual treatment . The objective study ass appropriateness necessity revision standardize criterion image interpretation In-111 Zevalin compare assessment investigator member committee image interpretation In-111 Zevalin . A total 40 patient recruit .</brief_summary>
	<brief_title>Zevalin Post-marketing Surveillance Adequateness Image Interpretation Criteria Japan</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients receive In111 Zevalin verify expect biodistribution present . Patients contraindicate base product label .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Zevalin</keyword>
	<keyword>CD20+</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Mantle cell lymphoma</keyword>
</DOC>